Voya Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Voya Financial Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,213	Closed	-$234K	–	273
2022 Q1	$234K	Buy	2,213 +320	+17%	+$31.2K	0.03%	243
2021 Q4	$205K	Buy	+1,893	New	+$207K	0.02%	259
2021 Q2	–	Sell	-2,900	Closed	-$253K	–	659
2021 Q1	$253K	Buy	+2,900	New	+$245K	0.01%	582
2015 Q4	–	Sell	-46,456	Closed	-$780K	–	385
2015 Q3	$780K	Buy	+46,456	New	+$1.47M	0.14%	119

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Voya Financial Advisors's HZNP Position: Q2 2022 in Review

Voya Financial Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 2,213 shares — an estimated $234K sold.

Voya Financial Advisors first reported a position in HZNP in Q3 2015 and held it in 4 quarters. The position peaked at $780K in Q3 2015. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Voya Financial Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Voya Financial Advisors sold 2,213 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $234K.
Voya Financial Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 4 quarters.
Voya Financial Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $780K in Q3 2015.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Voya Financial Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.